Tech Company Financing Transactions
ImmuneXcite Funding Round
Private investors participated in a $2.7 million funding round for ImmuneXcite. The round was announced by the company on 2/2/2017.
Transaction Overview
Company Name
Announced On
2/2/2017
Transaction Type
Debt
Amount
$2,672,359
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 47 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3 Forbes Rd.
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Website
Email Address
Overview
The mAbXcite platform is ImmuneXcite's proprietary product-focused drug discovery engine that represents a fundamentally new approach in the rapidly growing field of cancer immunotherapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eric Furfine
Chief Scientific Officer
Ifat Rubin-Bejerano
Browse more venture capital transactions:
Prev: 2/2/2017: RoosterBio venture capital transaction
Next: 2/2/2017: Trussle venture capital transaction
Share this article
Where The Data Comes From
We record funding rounds that are announced publicly. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs